ApoCell awarded $2.9 million from SAIC-Frederick Inc. to deliver a new platform for detection and molecular analysis of circulating tumor cells (CTCs) to the National Cancer Institute’s Pharmacodynamics Program HOUSTON (Aug. 10, 2011) —ApoCell, Inc. announced the award of a $2.9 million contract from SAIC-Frederick Inc. (SAIC-F), in support of […]

FOR IMMEDIATE RELEASE New technology expands types of circulating tumor cells (CTCs) detected in blood; accelerates potential for personalized cancer treatment. HOUSTON (June 1, 2011) — ApoCell, Inc. announced today that it has completed the first prototype to commercialize a revolutionary technology that improves the detection of more types of […]